Email updates

Keep up to date with the latest news and content from Genome Biology and BioMed Central.

Research news

Proteomic early detection of ovarian cancer

Tudor Toma

Author Affiliations

Genome Biology 2002, 3:spotlight-20020213-01  doi:10.1186/gb-spotlight-20020213-01


The electronic version of this article is the complete one and can be found online at:


Published:13 February 2002

© 2002 BioMed Central Ltd

Research news

Over 80% of ovarian cancers are diagnosed when the disease is at a late stage, with a consequent five-year survival rate of only around 35%. New technologies for the detection of early-stage ovarian cancer would therefore be of great benefit. In February 8 online edition of The Lancet, Emanuel Petricoin III and colleagues from the US Food and Drug Administration, Bethesda, show that computer-assisted detection of proteomic patterns could help in screening for ovarian cancer.

Petricoin et al. analysed blood proteins of women with ovarian cancer using mass spectroscopy and a novel computer-searching algorithm. They found a discriminatory proteomic pattern that correctly identified all 50 ovarian cancer cases and 63 of the 66 non-cancer cases from a set of 116 masked serum samples (sensitivity 100%; specificity 95%; positive predictive value 94%; Lancet 2002, 359:572-577).

"These findings justify a prospective population-based assessment of proteomic pattern technology, as a screening tool for all stages of ovarian cancer in high-risk and general populations," commented Emanuel Petricoin III.

References

  1. [http://www.thelancet.com] webcite

    Petricoin III EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Simone GS, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.

  2. [http://www.fda.gov] webcite

    Food and Drug Administration